Genvec Inc (GNVC)

7.19
0.02 0.24
NASDAQ : Health Care
Prev Close 7.21
Open 7.21
Day Low/High 7.01 / 7.25
52 Wk Low/High 0.35 / 3.69
Volume 12.93K
Avg Volume 28.20K
Exchange NASDAQ
Shares Outstanding 2.27M
Market Cap 16.35M
EPS -2.80
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

INVESTOR ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of GenVec, Inc. And Encourages Investors To Contact The Firm For Additional Information

The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of GenVec,...

SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of GenVec, Inc. And Encourages Investors To Contact The Firm For Additional Information

The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of GenVec,...

This Small-Cap Rotation Is Unconvincing

This Small-Cap Rotation Is Unconvincing

Traders, pressed to find some action, are chasing certain things to a ridiculous extent.

7 Stocks Under $10 Spiking Toward Big Gains

7 Stocks Under $10 Spiking Toward Big Gains

When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits

5 Stocks Under $10 Set to Soar Higher

These five stocks trading for less than $10 a share are within range of triggering breakout trades.

A Lack of News and Buzz at 'JPM16' Sinks Biotech Stocks

A Lack of News and Buzz at 'JPM16' Sinks Biotech Stocks

Biotech stocks large and small were plummeting as 2016's painful start began to turn torturous.

3 Stocks Pushing The Drugs Industry Lower

3 Stocks Pushing The Drugs Industry Lower

TheStreet highlights 3 stocks pushing the Drugs industry lower today.

Why GenVec (GNVC) Stock Is Up In Aftermarket Trading

Why GenVec (GNVC) Stock Is Up In Aftermarket Trading

Shares of GenVec (GNVC) were up 12.83% to $2.99 in aftermarket trading Thursday.

3 Biotech Stocks Under $10 Triggering Breakouts

3 Biotech Stocks Under $10 Triggering Breakouts

Keep an eye on these under-$10 biotech stocks.

GenVec's CEO Discusses Q2 2012 Results - Earnings Call Transcript

GenVec's CEO Discusses Q2 2012 Results - Earnings Call Transcript

GenVec's CEO Discusses Q2 2012 Results - Earnings Call Transcript

Deadline Approaching: The Law Firm Of Levi & Korsinsky Notifies Investors With Losses On Their Investment In GenVec, Inc. Of Class Action Lawsuit And The Deadline Of April 6, 2012 To Seek A Lead Plaintiff Position

Deadline Approaching: The Law Firm Of Levi & Korsinsky Notifies Investors With Losses On Their Investment In GenVec, Inc. Of Class Action Lawsuit And The Deadline Of April 6, 2012 To Seek A Lead Plaintiff Position

Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of Maryland on behalf of investors who purchased GenVec, Inc.

The Law Firm Of Levi & Korsinsky Notifies Investors With Losses On Their Investment In GenVec, Inc. Of Class Action Lawsuit And The Deadline Of April 6, 2012 To Seek A Lead Plaintiff Position

The Law Firm Of Levi & Korsinsky Notifies Investors With Losses On Their Investment In GenVec, Inc. Of Class Action Lawsuit And The Deadline Of April 6, 2012 To Seek A Lead Plaintiff Position

Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of Maryland on behalf of investors who purchased GenVec, Inc.

Law Firm Brower Piven Announces Investigation Of Investor Securities Fraud Against GenVec, Inc.

Law Firm Brower Piven Announces Investigation Of Investor Securities Fraud Against GenVec, Inc.

The law firm of Brower Piven, A Professional Corporation, is investigating potential securities fraud claims against GenVec, Inc.

GenVec Value Slammed on Drug Failure

The blowup of GenVec's drug for pancreatic cancer in a phase III study reduces fair value to around 30 cents a share.

GenVec, Encorium Group: Early Volume Plays

Several stocks trading near $5 were poised to move on above-average volume during Tuesday's session.

10 Biotech Stocks On the Line

Here are ten biotech and drug companies facing upcoming, potentially stock-moving events.

Biotech Calendar: Key Dates for March

March's list of important, potentially stock-moving biotech events

Biotech Stock Mailbag: Rexahn Pharma

In a bonus edition of Mailbag, our biotech columnist answers readers' questions about healthcare stocks and the FDA.

Early Volume Plays: Novavax, GenVec

Several stocks trading near or under $5 were poised to move on above-average volume during Friday's trading session.

10 Biotech Stocks on Clinical Trials Watch

News of clinical trial results can make or break a drug. Here are ten companies expected to announce important results in coming months.

Biotech Stock Mailbag: Keryx Biopharmaceuticals

Columnist Adam Feuerstein reports on fan mail, hate mail and readers' queries about Keryx and other biotech stocks.

Conolog, Jackson Hewitt: Late Day Volume Plays

Several stocks trading near $5 were moving on above-average volume during Wednesday's session.

GenVec Financing Sinks Shares: BioBuzz

Offering comes right before data read-out from a crucial cancer drug trial.

Biotech Stock Mailbag: GenVec

Senior columnist Adam Feuerstein responds to readers' biotech stock questions -- and lets Adventrx Pharmaceuticals' CEO sound off in response to a couple recent columns.

Biotech Stock Mailbag Readers' Portfolio

Introducing the Biotech Stock Mailbag Readers' Portfolio, which highlights stocks picked by readers and regularly-updated analysis from columnist Adam Feuerstein.

GenVec, Allied Defense: Early Volume Plays

Several stocks trading near $5 were poised to move on above-average volume during Tuesday's session.